Literature DB >> 12744808

Rationale for the use of cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs in ankylosing spondylitis: the available evidence.

Lars Köehler1, Jens G Kuipers, Henning Zeidler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12744808     DOI： 10.1007/s11926-003-0062-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  17 in total

1.  Safety of celecoxib vs other nonsteroidal anti-inflammatory drugs.

Authors:  L Köhler; H Zeidler; S Merkesdal; J G Kuipers
Journal:  JAMA       Date:  2000-12-27       Impact factor: 56.272

2.  Medication toxicity among patients with ankylosing spondylitis.

Authors:  Michael M Ward; Susana Kuzis
Journal:  Arthritis Rheum       Date:  2002-06-15

3.  Treatments used by patients with ankylosing spondylitis comparison with the treatment preferences of rheumatologists.

Authors:  M M Ward; S Kuzis
Journal:  J Clin Rheumatol       Date:  1999-02       Impact factor: 3.517

4.  A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation.

Authors:  A D McMahon; J M Evans; G White; F E Murray; M M McGilchrist; D G McDevitt; T M MacDonald
Journal:  J Clin Epidemiol       Date:  1997-03       Impact factor: 6.437

5.  Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany.

Authors:  Henning Zeidler; Joachim P Kaltwasser; Joachim P Leonard; Thomas Kohlmann; Ralf Sigmund; Frank Degner; Marceline Hettich
Journal:  J Clin Rheumatol       Date:  2002-12       Impact factor: 3.517

6.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Authors:  M J Langman; D M Jensen; D J Watson; S E Harper; P L Zhao; H Quan; J A Bolognese; T J Simon
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

7.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.

Authors:  J W Boersma
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

8.  Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.

Authors:  M Dougados; A Gueguen; J P Nakache; P Velicitat; E M Veys; H Zeidler; A Calin
Journal:  Rheumatology (Oxford)       Date:  1999-03       Impact factor: 7.580

Review 9.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis.

Authors:  A Calin; J Elswood
Journal:  J Rheumatol       Date:  1990-06       Impact factor: 4.666
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.